carbidopa monohydrate: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
carbidopa monohydrate: clinical details
Prescribing considerations
- Carbidopa is used with levodopa; individualise treatment according to clinical response and adverse effects.
- Avoid abrupt withdrawal because a syndrome resembling neuroleptic malignant syndrome may occur.
- Review somnolence, sudden sleep, dyskinesia, psychosis, impulse-control disorders and dopamine dysregulation symptoms.
- Use caution with cardiovascular, pulmonary, renal, hepatic or endocrine disease, asthma, previous peptic ulceration, convulsions or controlled wide-angle glaucoma.
- Formulation changes and swallowing interventions should involve the specialist team.
Contraindications and cautions
- Hypersensitivity to carbidopa, levodopa or an excipient
- Concomitant non-selective MAO inhibition or selective MAO-A inhibition
- Narrow-angle glaucoma
- Suspicious undiagnosed skin lesions or previous melanoma
- Phaeochromocytoma, hyperthyroidism, Cushing's syndrome or severe cardiovascular disease
- Severe psychosis
- Pregnancy where maternal benefit does not outweigh possible fetal risk
Monitoring
- Motor response, wearing-off, dyskinesia and other involuntary movements
- Postural blood pressure, sleepiness and sudden sleep onset
- Mood, psychosis, impulse-control disorders and compulsive overuse
- Periodic hepatic, haematological, cardiovascular and renal assessment during extended treatment
- Intraocular pressure in controlled wide-angle glaucoma
- Regular skin surveillance for melanoma
Clinical pharmacology
Carbidopa inhibits peripheral aromatic amino-acid decarboxylase and does not meaningfully cross the blood–brain barrier. It increases levodopa bioavailability and reduces its peripheral conversion to dopamine.
Formulation and product differences
- The selected product is an immediate-release oral tablet.
- If it breaks during removal, all pieces must be taken; a partial tablet may worsen symptom control.
- Immediate-release tablets can be dispersed or mixed with soft food off-label following professional direction.
- Modified-release co-careldopa products must not be crushed or switched without specialist input.
carbidopa monohydrate interactions
Check all prescribed, non-prescribed and complementary products with a pharmacist or prescriber.
Non-selective MAO inhibitors and selective MAO-A inhibitors
The combination is contraindicated because serious cardiovascular reactions may occur; recent use requires prescriber review.
Iron preparations
Iron can reduce carbidopa or levodopa availability. Seek professional advice about separating administration.
Antihypertensive medicines
May worsen postural hypotension, causing dizziness or fainting.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.